Categories
Change Password!
Reset Password!
This study evaluated the effectiveness of corticosteroids taken orally and olfactory training as a therapy for persistent olfactory dysfunction (loss of smell) due to COVID-19.
Olfactory loss is well
reported symptom of COVID-19. Given the need to find a standardized treatment
to lessen the risk of developing long-term olfactory illness in COVID patients,
this study found that the use of oral corticosteroids and olfactory training may be effective in
these patients.
This study evaluated the effectiveness of corticosteroids taken orally and
olfactory training as a therapy for persistent olfactory dysfunction (loss of
smell) due to COVID-19.
This pilot study included non-hospitalized patients with
unexpected loss of smell and positive COVID-19. Persistent dysosmia was
identified in these patients via psychophysical testing. Thereafter, these
patients were subjected to a course of oral corticosteroids plus olfactory
training for 10 days (9 patients), or just olfactory training (18 patients).
Following 10 weeks, all patients were subjected to another olfactory test.
Patients on corticosteroids taken orally plus
olfactory training portrayed considerable improved olfactory score (threshold
discrimination identification / TDI score) and negligible clinically important
difference for subjective improvement of smell (p = 0.007). Minimum and
temporary side effects were observed in 3 patients with oral corticosteroids.
Oral corticosteroids along with olfactory training when used
for short duration are effective and safe in patients with ongoing dysosmia
recovery from olfactory loss as a result of COVID-19. Future examination to
validate these conclusions is required.
European Archives of Oto-Rhino-Laryngology
Efficacy and safety of oral corticosteroids and olfactory training in the management of COVID-19-related loss of smell
Serge-Daniel Le Bon et al.
Comments (0)